BTAI BioXcel Therapeutics Inc

BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced it will host a conference call and webcast on Monday, March 9, 2020 at 8:30 AM Eastern Time to discuss its fourth quarter and full year 2019 operating and financial results.

Conference Call & Webcast Details

Date/Time: Monday, March 9, 2020, 8:30 AM Eastern TimeDomestic: 877-407-2985International: 201-378-4915

The webcast will be accessible* under "Events" on the News & Media page of the Company's website at www.bioxceltherapeutics.com.

ReplayDomestic: 877-660-6853International: 201-612-7415Conference ID: 13696573

*Replay available through March 23, 2020

About BioXcel Therapeutics, Inc.:

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit www.bioxceltherapeutics.com.

Contact Information:

BioXcel Therapeutics, Inc.www.bioxceltherapeutics.com

Investor Relations: John Graziano jgraziano@troutgroup.com1.646.378.2942

Media: Julia Deutsch jdeutsch@troutgroup.com1.646.378.2967